The use of autologous serum eye drops for the treatment of ocular surface disorders
ObjectivesTo investigate the use of autologous serum (AS) eye drops in patients with ocular surface disorders who were refractory to conventional treatments.MethodsA retrospective cohort study was conducted at a tertiary care centre. We included patients with a prescription of AS eye drops from Dece...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2019-11, Vol.26 (6), p.314-317 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 317 |
|---|---|
| container_issue | 6 |
| container_start_page | 314 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 26 |
| creator | García-Martín, Estela Pernía-López, Sagrario Romero Jiménez, RM García-Valcárcel, Blanca Martínez-Ortega, Pilar A Sanjurjo-Saez, María |
| description | ObjectivesTo investigate the use of autologous serum (AS) eye drops in patients with ocular surface disorders who were refractory to conventional treatments.MethodsA retrospective cohort study was conducted at a tertiary care centre. We included patients with a prescription of AS eye drops from December 2006 to January 2016. Electronic prescriptions (Prescriplant) and clinical histories were reviewed. A database with sociodemographic and pharmacotherapheutic variables was created. The efficacy was evaluated subjectively and adverse effects was a measurement of safety. AS eye drops were elaborated, in a laminar flow hood, with the blood samples for a final concentration of 20%.ResultsOne hundred and seventy-three patients were considered for the study, 78.03% of them female. Their mean age was 63.87 years (SD 16.69). The use of AS eye drops was indicated for several diseases: corneal diseases (corneal ulcer or corneal persistent epithelial defects) (34.32%); Sjögren syndrome (17.16%); dry eye resulting from autoimmune disease (15.38%); and blepharitis/blepharospasm (12.43%). The regular dosage was every 3 or 4 hours (40.46%). 21.97% patients used the AS in one eye only. The mean length of treatment was 2.71 years. All patients, except one, improved their symptoms with the treatment and no one suffered harmful effects.ConclusionsNumerous national and international guidelines on dry eye treatment have been published, but they differ in dosing, concentration and indication of AS eye drops. Consequently, there is no consensus about the best therapy with AS. In this article we describe the clinical practice of AS eye drops. In the study, indications for AS therapy were mostly: corneal diseases; Sjögren syndrome; and dry eye resulting from autoimmune disease; and blepharitis or blepharospasm. Patients went to the hospital pharmacy to pick up AS eye drops before 90 days, it ensures the stability of eye drops. AS is an effective, safe and well tolerated treatment. |
| doi_str_mv | 10.1136/ejhpharm-2018-001527 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6855871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2321674792</sourcerecordid><originalsourceid>FETCH-LOGICAL-b476t-414ea70699f29fbad82ff0234cab02503454d89c0d8aebe72185db8f8f41252c3</originalsourceid><addsrcrecordid>eNqNkU1rGzEQhkVJqU2af1CKIJdcttbnSroUgknbQKCHpmeh3R3Za3YtV1oF_O8j49g0OeWkAT3zMjMPQl8o-UYprxewWe_WLo4VI1RXhFDJ1Ac0Z0SoyphaXJxrWc_QVUp9QyTn2ghuPqEZp8poLfkc_XlcA84JcPDY5SkMYRVywgliHjHsAXcx7BL2IeKpkFMEN42wnQ58aPPgIk45etcWsk8hdhDTZ_TRuyHB1ct7if7-uHtc_qoefv-8X94-VI1Q9VQJKsApUhvjmfGN6zTznjAuWtcQJgkXUnTatKTTDhpQjGrZNdprLyiTrOWX6Psxd5ebEbq2jBXdYHexH13c2-B6-_pn26_tKjzZWkupFS0BNy8BMfzLkCY79qmFYXBbKFewjDNaK6EMK-j1G3QTctyW9QpFysmVEXWhxJFqY0gpgj8PQ4k9iLMncfYgzh7Flbav_y9ybjppKsDiCDTj5n2Rz-yMpnk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309967946</pqid></control><display><type>article</type><title>The use of autologous serum eye drops for the treatment of ocular surface disorders</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>García-Martín, Estela ; Pernía-López, Sagrario ; Romero Jiménez, RM ; García-Valcárcel, Blanca ; Martínez-Ortega, Pilar A ; Sanjurjo-Saez, María</creator><creatorcontrib>García-Martín, Estela ; Pernía-López, Sagrario ; Romero Jiménez, RM ; García-Valcárcel, Blanca ; Martínez-Ortega, Pilar A ; Sanjurjo-Saez, María</creatorcontrib><description>ObjectivesTo investigate the use of autologous serum (AS) eye drops in patients with ocular surface disorders who were refractory to conventional treatments.MethodsA retrospective cohort study was conducted at a tertiary care centre. We included patients with a prescription of AS eye drops from December 2006 to January 2016. Electronic prescriptions (Prescriplant) and clinical histories were reviewed. A database with sociodemographic and pharmacotherapheutic variables was created. The efficacy was evaluated subjectively and adverse effects was a measurement of safety. AS eye drops were elaborated, in a laminar flow hood, with the blood samples for a final concentration of 20%.ResultsOne hundred and seventy-three patients were considered for the study, 78.03% of them female. Their mean age was 63.87 years (SD 16.69). The use of AS eye drops was indicated for several diseases: corneal diseases (corneal ulcer or corneal persistent epithelial defects) (34.32%); Sjögren syndrome (17.16%); dry eye resulting from autoimmune disease (15.38%); and blepharitis/blepharospasm (12.43%). The regular dosage was every 3 or 4 hours (40.46%). 21.97% patients used the AS in one eye only. The mean length of treatment was 2.71 years. All patients, except one, improved their symptoms with the treatment and no one suffered harmful effects.ConclusionsNumerous national and international guidelines on dry eye treatment have been published, but they differ in dosing, concentration and indication of AS eye drops. Consequently, there is no consensus about the best therapy with AS. In this article we describe the clinical practice of AS eye drops. In the study, indications for AS therapy were mostly: corneal diseases; Sjögren syndrome; and dry eye resulting from autoimmune disease; and blepharitis or blepharospasm. Patients went to the hospital pharmacy to pick up AS eye drops before 90 days, it ensures the stability of eye drops. AS is an effective, safe and well tolerated treatment.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2018-001527</identifier><identifier>PMID: 31798853</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Computerized physician order entry ; Defects ; Eye care products ; Eye diseases ; Eye surgery ; Growth factors ; Hospitals ; Literature reviews ; Original ; Patients ; Pharmacists</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2019-11, Vol.26 (6), p.314-317</ispartof><rights>European Association of Hospital Pharmacists 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2019 European Association of Hospital Pharmacists 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2019. No commercial re-use. See rights and permissions. Published by BMJ. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b476t-414ea70699f29fbad82ff0234cab02503454d89c0d8aebe72185db8f8f41252c3</citedby><cites>FETCH-LOGICAL-b476t-414ea70699f29fbad82ff0234cab02503454d89c0d8aebe72185db8f8f41252c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855871/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855871/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31798853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Martín, Estela</creatorcontrib><creatorcontrib>Pernía-López, Sagrario</creatorcontrib><creatorcontrib>Romero Jiménez, RM</creatorcontrib><creatorcontrib>García-Valcárcel, Blanca</creatorcontrib><creatorcontrib>Martínez-Ortega, Pilar A</creatorcontrib><creatorcontrib>Sanjurjo-Saez, María</creatorcontrib><title>The use of autologous serum eye drops for the treatment of ocular surface disorders</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>ObjectivesTo investigate the use of autologous serum (AS) eye drops in patients with ocular surface disorders who were refractory to conventional treatments.MethodsA retrospective cohort study was conducted at a tertiary care centre. We included patients with a prescription of AS eye drops from December 2006 to January 2016. Electronic prescriptions (Prescriplant) and clinical histories were reviewed. A database with sociodemographic and pharmacotherapheutic variables was created. The efficacy was evaluated subjectively and adverse effects was a measurement of safety. AS eye drops were elaborated, in a laminar flow hood, with the blood samples for a final concentration of 20%.ResultsOne hundred and seventy-three patients were considered for the study, 78.03% of them female. Their mean age was 63.87 years (SD 16.69). The use of AS eye drops was indicated for several diseases: corneal diseases (corneal ulcer or corneal persistent epithelial defects) (34.32%); Sjögren syndrome (17.16%); dry eye resulting from autoimmune disease (15.38%); and blepharitis/blepharospasm (12.43%). The regular dosage was every 3 or 4 hours (40.46%). 21.97% patients used the AS in one eye only. The mean length of treatment was 2.71 years. All patients, except one, improved their symptoms with the treatment and no one suffered harmful effects.ConclusionsNumerous national and international guidelines on dry eye treatment have been published, but they differ in dosing, concentration and indication of AS eye drops. Consequently, there is no consensus about the best therapy with AS. In this article we describe the clinical practice of AS eye drops. In the study, indications for AS therapy were mostly: corneal diseases; Sjögren syndrome; and dry eye resulting from autoimmune disease; and blepharitis or blepharospasm. Patients went to the hospital pharmacy to pick up AS eye drops before 90 days, it ensures the stability of eye drops. AS is an effective, safe and well tolerated treatment.</description><subject>Computerized physician order entry</subject><subject>Defects</subject><subject>Eye care products</subject><subject>Eye diseases</subject><subject>Eye surgery</subject><subject>Growth factors</subject><subject>Hospitals</subject><subject>Literature reviews</subject><subject>Original</subject><subject>Patients</subject><subject>Pharmacists</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkU1rGzEQhkVJqU2af1CKIJdcttbnSroUgknbQKCHpmeh3R3Za3YtV1oF_O8j49g0OeWkAT3zMjMPQl8o-UYprxewWe_WLo4VI1RXhFDJ1Ac0Z0SoyphaXJxrWc_QVUp9QyTn2ghuPqEZp8poLfkc_XlcA84JcPDY5SkMYRVywgliHjHsAXcx7BL2IeKpkFMEN42wnQ58aPPgIk45etcWsk8hdhDTZ_TRuyHB1ct7if7-uHtc_qoefv-8X94-VI1Q9VQJKsApUhvjmfGN6zTznjAuWtcQJgkXUnTatKTTDhpQjGrZNdprLyiTrOWX6Psxd5ebEbq2jBXdYHexH13c2-B6-_pn26_tKjzZWkupFS0BNy8BMfzLkCY79qmFYXBbKFewjDNaK6EMK-j1G3QTctyW9QpFysmVEXWhxJFqY0gpgj8PQ4k9iLMncfYgzh7Flbav_y9ybjppKsDiCDTj5n2Rz-yMpnk</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>García-Martín, Estela</creator><creator>Pernía-López, Sagrario</creator><creator>Romero Jiménez, RM</creator><creator>García-Valcárcel, Blanca</creator><creator>Martínez-Ortega, Pilar A</creator><creator>Sanjurjo-Saez, María</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191101</creationdate><title>The use of autologous serum eye drops for the treatment of ocular surface disorders</title><author>García-Martín, Estela ; Pernía-López, Sagrario ; Romero Jiménez, RM ; García-Valcárcel, Blanca ; Martínez-Ortega, Pilar A ; Sanjurjo-Saez, María</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b476t-414ea70699f29fbad82ff0234cab02503454d89c0d8aebe72185db8f8f41252c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Computerized physician order entry</topic><topic>Defects</topic><topic>Eye care products</topic><topic>Eye diseases</topic><topic>Eye surgery</topic><topic>Growth factors</topic><topic>Hospitals</topic><topic>Literature reviews</topic><topic>Original</topic><topic>Patients</topic><topic>Pharmacists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Martín, Estela</creatorcontrib><creatorcontrib>Pernía-López, Sagrario</creatorcontrib><creatorcontrib>Romero Jiménez, RM</creatorcontrib><creatorcontrib>García-Valcárcel, Blanca</creatorcontrib><creatorcontrib>Martínez-Ortega, Pilar A</creatorcontrib><creatorcontrib>Sanjurjo-Saez, María</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Proquest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Martín, Estela</au><au>Pernía-López, Sagrario</au><au>Romero Jiménez, RM</au><au>García-Valcárcel, Blanca</au><au>Martínez-Ortega, Pilar A</au><au>Sanjurjo-Saez, María</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of autologous serum eye drops for the treatment of ocular surface disorders</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><addtitle>Eur J Hosp Pharm</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>26</volume><issue>6</issue><spage>314</spage><epage>317</epage><pages>314-317</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>ObjectivesTo investigate the use of autologous serum (AS) eye drops in patients with ocular surface disorders who were refractory to conventional treatments.MethodsA retrospective cohort study was conducted at a tertiary care centre. We included patients with a prescription of AS eye drops from December 2006 to January 2016. Electronic prescriptions (Prescriplant) and clinical histories were reviewed. A database with sociodemographic and pharmacotherapheutic variables was created. The efficacy was evaluated subjectively and adverse effects was a measurement of safety. AS eye drops were elaborated, in a laminar flow hood, with the blood samples for a final concentration of 20%.ResultsOne hundred and seventy-three patients were considered for the study, 78.03% of them female. Their mean age was 63.87 years (SD 16.69). The use of AS eye drops was indicated for several diseases: corneal diseases (corneal ulcer or corneal persistent epithelial defects) (34.32%); Sjögren syndrome (17.16%); dry eye resulting from autoimmune disease (15.38%); and blepharitis/blepharospasm (12.43%). The regular dosage was every 3 or 4 hours (40.46%). 21.97% patients used the AS in one eye only. The mean length of treatment was 2.71 years. All patients, except one, improved their symptoms with the treatment and no one suffered harmful effects.ConclusionsNumerous national and international guidelines on dry eye treatment have been published, but they differ in dosing, concentration and indication of AS eye drops. Consequently, there is no consensus about the best therapy with AS. In this article we describe the clinical practice of AS eye drops. In the study, indications for AS therapy were mostly: corneal diseases; Sjögren syndrome; and dry eye resulting from autoimmune disease; and blepharitis or blepharospasm. Patients went to the hospital pharmacy to pick up AS eye drops before 90 days, it ensures the stability of eye drops. AS is an effective, safe and well tolerated treatment.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>31798853</pmid><doi>10.1136/ejhpharm-2018-001527</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2019-11, Vol.26 (6), p.314-317 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6855871 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Computerized physician order entry Defects Eye care products Eye diseases Eye surgery Growth factors Hospitals Literature reviews Original Patients Pharmacists |
| title | The use of autologous serum eye drops for the treatment of ocular surface disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T05%3A50%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20autologous%20serum%20eye%20drops%20for%20the%20treatment%20of%20ocular%20surface%20disorders&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Garc%C3%ADa-Mart%C3%ADn,%20Estela&rft.date=2019-11-01&rft.volume=26&rft.issue=6&rft.spage=314&rft.epage=317&rft.pages=314-317&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2018-001527&rft_dat=%3Cproquest_pubme%3E2321674792%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2309967946&rft_id=info:pmid/31798853&rfr_iscdi=true |